Cooper Companies Inc
F:CP60
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Cooper Companies Inc
F:CP60
|
US |
|
Prysmian SpA
LSE:0NUX
|
IT |
|
U
|
Under Armour Inc
XBER:U9R
|
US |
|
S
|
Steven Madden Ltd
XBER:SJM
|
US |
Cooper Companies Inc
Cooper Companies makes medical products in two main areas: contact lenses and women’s health. Through CooperVision, it sells soft contact lenses for nearsightedness, farsightedness, astigmatism, and presbyopia to eye doctors, optometrists, retailers, and patients. Through CooperSurgical, it sells tools and devices used by fertility clinics, hospitals, and other women’s health providers. The company makes money by manufacturing these products and selling them to healthcare professionals and distributors. A large part of its business comes from recurring use: contact lenses are replaced regularly, and many of its surgical and fertility products are used in ongoing clinical procedures. That gives Cooper a mix of everyday consumer-style demand and professional healthcare demand. What makes Cooper’s business different is that it sits in two specialized niches with long-term customer relationships. In vision care, it focuses on products people need to wear every day, while in women’s health it supplies equipment and consumables used in clinics and hospitals. That combination gives the company a steady role in both routine eye care and specialized medical procedures.
Cooper Companies makes medical products in two main areas: contact lenses and women’s health. Through CooperVision, it sells soft contact lenses for nearsightedness, farsightedness, astigmatism, and presbyopia to eye doctors, optometrists, retailers, and patients. Through CooperSurgical, it sells tools and devices used by fertility clinics, hospitals, and other women’s health providers.
The company makes money by manufacturing these products and selling them to healthcare professionals and distributors. A large part of its business comes from recurring use: contact lenses are replaced regularly, and many of its surgical and fertility products are used in ongoing clinical procedures. That gives Cooper a mix of everyday consumer-style demand and professional healthcare demand.
What makes Cooper’s business different is that it sits in two specialized niches with long-term customer relationships. In vision care, it focuses on products people need to wear every day, while in women’s health it supplies equipment and consumables used in clinics and hospitals. That combination gives the company a steady role in both routine eye care and specialized medical procedures.
Record quarter: Cooper reported record revenue of $1.08 billion and record non-GAAP EPS of $1.21, with both metrics up strongly year over year.
Asia Pac weakens: CooperVision’s outlook was trimmed because Asia Pac demand softened, especially in Japan and China, and the company said that region is weighing on near-term growth.
CSI review advances: Management said it has received significant interest in CooperSurgical, has settled the fertility litigation, and is now moving quickly on strategic options.
Cash flow strong: Free cash flow was $96 million this quarter, and full-year free cash flow guidance was raised to about $650 million, despite the litigation settlement.
Margins helped by efficiency: Operating margin expanded to 27.5% as back-office consolidation, lower expenses, and better inventory control drove leverage.
Buybacks to pick up: Share repurchases were light in the quarter, but management said it expects to be much more active going forward.
